<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bittner, Dennis</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Slotman, Ben</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">TRT in Addition to PCI Improves Outcomes for ES-SCLC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-10</style></pages><abstract><style  face="normal" font="default" size="100%">Prophylactic cranial irradiation in the treatment of extensive-stage small cell lung cancer has proven value in reducing symptomatic brain metastases and in improving overall survival at 1 year. However, persistent intrathoracic disease occurs in 76% of such patients and intrathoracic disease progresses in almost 90% of this group. This article discusses data from the Chest Radiotherapy Extensive Stage Trial [CREST; NTR1527] that evaluated the use of thoracic radiotherapy in addition to PCI for treatment of ES-SCLC to prevent occurrence of thoracic disease and halt its progression.</style></abstract><number><style face="normal" font="default" size="100%">31</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>